Abstract
Introduction/aimOmalizumab (Xolair) is a recombinant humanised monoclonal antibody licensed for the treatment of severe allergic asthma patients with IgE mediated disease. The mechanism of action of omalizumab is to bind...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have